DEVICE FOR THE LIFE-LONG ADMINISTRATION OF VARYING DOSES OF A GEROPROTECTOR AND FOR INCREASING HORMESIS POST-ADAPTATION

Abstract

The technical result of the invention is structurally creation of a biotechnical system of common blister pack elements consistently providing the drug substance with excellent ways of delivering a solid therapeutic dose orally or a liquid subtherapeutic dose sublingually.

The combination of individual separate delivery routes for solid therapeutic dose orally or a subtherapeutic liquid dose sublingually is a qualitatively new structural pharmacotherapy unit enabling the postadaptation hormesis effect. The advantage of the new drug form is elimination of the pre-systemic metabolism effect in liver with a subtherapeutic dose along with systemic bioavailability enhancement, prevention of drug destruction by chlorobutanol acid in the stomach and by alkaline contents in the intestines, and body resistance improvement.

Claims

1. Blister pack in which the film-substrate formed with blisters, attached to a flat film of height and which contains at least two parallel rows of blisters, wherein the blisters in one row with a solid drug located in front of the other blisters of a number of liquid form of the drug with the possibility of printing blisters with liquid form of the drug along the lines of cuts only after opening the blister with a solid form of the drug.

2. Blister pack according to claim 1 is characterized by notching lines on a flat film covering for opening the liquid drug form being arranged above the solid form blister.

3. Blister pack according to claim 1 is characterized by perforations executed with a possibility of separation from the blister pack of individual blister units containing a solid or a liquid drug dose.

4. Blister pack according to claim 1 is characterized by the possibility for the solid dose blister to be filled with a therapeutic dose in tablets, capsules, dragees, granules, or powder.

5. (canceled)

6. (canceled)

7. (canceled)

Description

EXAMPLE 1

[0033] Woman aged 36, blood donor, common hemoglobin 125-135. In the morning, she took 250 mg of taurine orally in tablets for 2 weeks as a preventive measure. At the next blood donation, hemoglobin was 103. The donor underwent the medical examination, and no specific disease was identified. In animal studies it was discovered that taurine amino acid is capable of lowering hemoglobin in blood [22].

[0034] Donor's hemoglobin value was adjusted by the post-adaptation hormesis effect with a solid and a liquid sub-therapeutic taurine dose. A taurine blister pack with a solid dose of 250 mg was used for oral administration in the morning and with a liquid subtherapeutic dose of 25 mg sublingually at night. After 2 weeks of taurine intake in these doses, the condition was subjectively improved, and performance capabilities increased. Donor's hemoglobin value was back to normal130. Thus, use of blister packaging of solid and liquid subtherapeutic drug doses enables increasing the post-adaptation hormesis effect.

[0035] For these reasons, production of pharmaceutical taurine drug in blister packaging with a solid and liquid therapeutic sub therapeutic dose is advantageous.

[0036] The list of documents quoted in the search report: [0037] D1 RU 2314786 C2 20 Jan. 2008 [0038] D2 RU 2548476 C2 20 Apr. 2015 [0039] D3 RU 2483708 C2 10 Jun. 2013 [0040] D4 U.S. Pat. No. 6,253,920 B1 3 Jul. 2001 [0041] [5] http://www.scienceagainstaging.com/Books/OBZOR_razvorot-final.pdf [0042] [6] http://cancerres.aacrjournals.org/content/74/19_Supplement/2153.abstract [0043] [7] http://www.ncbi.nlm.nih.gov/pubmed/24647393 [0044] [8] http://www.nature.com/nchembio/journal/v9/n11/full/nchembio.1352.html [0045] [9] http://www.ncbi.nlm.nih.gov/pubmed/9972141 [0046] [10] http://link.springer.com/article/10.1007%252Fs10654-012-9714-6 [0047] [11] 7Dose-Response, 9:209-224, 2011 Formerly Nonlinearity in Biology, Toxicology, and Medicine Copyright 2011 University of Massachusetts ISSN: 1559-3258 DOI: 10.2203/dose-response.10-004.Wiegant [0048] [12] Pharmaceutics technology (in two volumes) Ed. by L. A. Ivanova.M., Medicine, 1991. [0049] [13] http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813349/[14] [0050] [14] https://www.ncbi.nlm.nih.gov/pubmed/18407290 [0051] [15] https://www.ncbi.nlm.nih.gov/pubmed/11510759 [0052] [16] https://www.ncbi.nlm.nih.gov/pubmed/22903433 [0053] [17] https://link.springer.com/leaf-pricing/chapter/10.1007/978-3-319-15126-7_45 [0054] [18] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994395/[19] [0055] [19] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994395/[20] [0056] [20] https://www.ncbi.nlm.nih.gov/pubmed/1138364 [0057] [21] https://www.ncbi.nlm.nih.gov/pubmed/3616607 [0058] [22] https://www.ncbi.nlm.nih.gov/pubmed/21850928